Incyte Corporation (INCY) Stock

About Incyte Corporation

Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.

Incyte Corporation is led by CEO William J. Meury, employs 2,844 people, headquartered in Wilmington, US, publicly traded since 1993.

Incyte Corporation (INCY) stock trades at $129.03 with a market capitalization of $25.78B. The stock is valued at a price-to-earnings (P/E) ratio of 14.00, price-to-book of 3.53, price-to-sales of 3.55. Over the past 52 weeks the stock has ranged between $59.15 and $129.03, and currently trades at its 52-week high.

On profitability, Incyte Corporation generates a return on equity (ROE) of 30.82% — well above the market average, a sign of a high-quality business, return on capital employed of 26.05%, an operating margin of 25.55%, a net profit margin of 26.71%.

In its most recent fiscal year, Incyte Corporation reported annual revenue of $5.1B, net profit of $1.3B, revenue has compounded at 14.0% a year over the last five years.

The balance sheet shows a debt-to-equity ratio of 0.01 — a conservative balance sheet with little leverage risk, a current ratio of 3.68, total assets of $7.0B, $3.1B in cash and equivalents.

INCY has an average daily trading volume of 1,810,916 shares, a beta of 0.79 (less volatile than the overall market).

Official website: www.incyte.com